Relación entre comorbilidad, anemia y respuesta a derivados eritropoyéticos en pacientes incluidos en programa de hemodiálisis periódicas

SUMMARY Introduction: Patients treated with haemodialysis have a high prevalence of co-morbidity that induces a elevate mortality risk. On the other hand, these patients have anaemia whose treat- ment is based in eritropoyesis stimulating agents. To date there are not enough studies to determine if co-morbidity alters eryth- ropoietin response and the relationship between co-morbidity, response to treatment of anaemia and resistance to erythro- poiesis-stimulating agents. Objectives: We have the following Objectives: i) to study the prevalence of associated diseases in patients treated with haemodialysis in our Hospital Unit and to evaluate the co-morbidity Charlson Index; ii) to know the degree of anaemia control, dose and response to erythropoiesis-stimu- lating agents, and iii) to determine the relationship with co- morbidity and anaemia treatment. Patients and methods: We designed a retrospective study in stable haemodialysis treated patients. We calculated the Charlson co-morbidity index adjus- ted to age and we analysed levels of haemoglobin in the 6 months before study, dose of erythropoiesis-stimulating agents